Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2
Joseph E. Klebba(Vividion Therapeutics (United States)), Matthew P. Patricelli(Vividion Therapeutics (United States)), Julian Downward(The Francis Crick Institute), Cynthia Berry(Vividion Therapeutics (United States)), Mona Tomaschko(The Francis Crick Institute), Kelsey N. Lamb(Vividion Therapeutics (United States)), Kenneth Hee(IDEXX Laboratories (France)), Chanyu Yue(Vividion Therapeutics (United States)), Melissa Hoffman(University of Cincinnati), Eric Walton(Vividion Therapeutics (United States)), Brian N. Cook(Vividion Therapeutics (United States)), Todd M. Kinsella(Vividion Therapeutics (United States)), Aaron N. Snead(Vividion Therapeutics (United States)), Igor Mochalkin(Vividion Therapeutics (United States)), Hui Miao(State Administration of Traditional Chinese Medicine of the People's Republic of China), Richard D. Lin(Vividion Therapeutics (United States)), Míriam Molina‐Arcas(The Francis Crick Institute), Benjamin D. Horning(Princeton University), Nilotpal Roy(Symbiosis International University), Steffen M. Bernard(Vividion Therapeutics (United States)), David S. Weinstein(National Bureau of Economic Research), Stephanie Grabow(Dana-Farber Cancer Institute), Joel M. Chick(Harvard University), Mohamed Ismail(The Francis Crick Institute), Erick Aitchison(Vividion Therapeutics (United States)), Marie Pariollaud(Scripps Research Institute), Taylor E. Wyrick(Vividion Therapeutics (United States)), Junko Tamiya(Vividion Therapeutics (United States)), Antonio Esparza-Oros(Vividion Therapeutics (United States)), Jinwei Wang(Fudan University), Lin Wei(Vividion Therapeutics (United States)), Gabriel M. Simon(Vividion Therapeutics (United States)), Jonathan Pollock(Vividion Therapeutics (United States)), Yongsheng Liu(Fujian Institute of Research on the Structure of Matter), Eileen Tran(Vividion Therapeutics (United States)), Martha K. Pastuszka(Vividion Therapeutics (United States)), J. Sigler(Vividion Therapeutics (United States)), Sareena Rana(The Francis Crick Institute), Karl Bedke(Vividion Therapeutics (United States)), Holly Parker(Vividion Therapeutics (United States))
Cited by 12
Related Papers
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
|Nature|1984|2.5k
Upconversion nanoparticles in biological labeling, imaging, and therapy
|The Analyst|2010|1.4k
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease
|Human Molecular Genetics|2005|566
An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action
|Nature Medicine|2014|463